Novo tightens pipeline and rebrands as Lilly closes obesity drug gap Brand trims name to Novo and resets R&D as Eli Lilly surges with Zepbound and Mounjaro

Here’s why Eli Lilly’s new mental-health deal signals a bigger shift beyond GLP-1 drugs.

QurCan Therapeutics and Lilly will develop nucleic acid therapies for CNS and PNS diseases. See what the partnership means for biotech.

The drugmaker has a lot riding on continued clinical progress.

A landmark trial just proved semaglutide can pull children as young as six below the obesity threshold, yet Wall Street shrugged and the real battle over who pays, who prescribes, and whether society is ready has barely begun.

Eli Lilly will present Phase 3 data for retatrutide, Foundayo, and other metabolic treatments at EASD 2026.

Berenberg upgrades Eli Lilly to Buy with a $1,400 target, citing GLP-1 demand, Foundayo catalysts, and M&A pipeline. Read more here.

It’s legal to pay practising physicians to promote specific drugs — and thousands are doing so.

A company-specific look at Eli Lilly, the current market theme surrounding LLY, its operating relevance and the evidence needed to assess what follows.

Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements...